Samantha Semenkow
Stock Analyst at Citigroup
(0.69)
# 3,733
Out of 4,784 analysts
41
Total ratings
25%
Success rate
-22.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIOA BioAge Labs | Maintains: Neutral | $7 → $5 | $3.82 | +30.89% | 3 | Mar 24, 2025 | |
| SLRN Acelyrin | Maintains: Neutral | $6 → $3 | $2.60 | +15.38% | 2 | Jan 7, 2025 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $12 | $3.65 | +228.77% | 1 | Dec 2, 2024 | |
| ARGX argenx SE | Maintains: Buy | $512 → $635 | $589.15 | +7.78% | 4 | Oct 17, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $7 → $8 | $1.55 | +416.13% | 2 | Aug 9, 2024 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $27 → $31 | $24.69 | +25.56% | 2 | Aug 9, 2024 | |
| SANA Sana Biotechnology | Maintains: Buy | $8 → $15 | $1.71 | +777.19% | 2 | Aug 9, 2024 | |
| SNSE Sensei Biotherapeutics | Reinstates: Buy | $4 | $0.51 | +686.94% | 2 | Jun 3, 2024 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $10 → $14 | $2.35 | +495.74% | 6 | May 22, 2024 | |
| PRME Prime Medicine | Upgrades: Buy | $10 | $1.99 | +402.51% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $1.25 | +1,100.00% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $4.95 | +142.42% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $30 | $1.55 | +1,835.48% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $39.86 | +80.63% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $18.37 | +172.18% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $22.21 | +152.14% | 3 | Aug 9, 2023 |
BioAge Labs
Mar 24, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $3.82
Upside: +30.89%
Acelyrin
Jan 7, 2025
Maintains: Neutral
Price Target: $6 → $3
Current: $2.60
Upside: +15.38%
Voyager Therapeutics
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $3.65
Upside: +228.77%
argenx SE
Oct 17, 2024
Maintains: Buy
Price Target: $512 → $635
Current: $589.15
Upside: +7.78%
Allogene Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $7 → $8
Current: $1.55
Upside: +416.13%
Catalyst Pharmaceuticals
Aug 9, 2024
Maintains: Buy
Price Target: $27 → $31
Current: $24.69
Upside: +25.56%
Sana Biotechnology
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $1.71
Upside: +777.19%
Sensei Biotherapeutics
Jun 3, 2024
Reinstates: Buy
Price Target: $4
Current: $0.51
Upside: +686.94%
Larimar Therapeutics
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $2.35
Upside: +495.74%
Prime Medicine
May 16, 2024
Upgrades: Buy
Price Target: $10
Current: $1.99
Upside: +402.51%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.25
Upside: +1,100.00%
Apr 8, 2024
Maintains: Buy
Price Target: $9 → $12
Current: $4.95
Upside: +142.42%
Apr 4, 2024
Maintains: Buy
Price Target: $26 → $30
Current: $1.55
Upside: +1,835.48%
Dec 8, 2023
Initiates: Buy
Price Target: $72
Current: $39.86
Upside: +80.63%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $18.37
Upside: +172.18%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $22.21
Upside: +152.14%